[1]王亚飞.振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血NT-proBNP、HCY水平的影响[J].医学信息,2022,35(21):88-91.[doi:10.3969/j.issn.1006-1959.2022.21.020]
　WANG Ya-fei.Clinical Efficacy of Zhenyuan Capsule in Adjuvant Treatment of Unstable Angina Pectoris and its Effect on Blood NT-proBNP and HCY Levels[J].Journal of Medical Information,2022,35(21):88-91.[doi:10.3969/j.issn.1006-1959.2022.21.020]
点击复制

振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血NT-proBNP、HCY水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
88-91
栏目:
论著
出版日期:
2022-11-01

文章信息/Info

Title:
Clinical Efficacy of Zhenyuan Capsule in Adjuvant Treatment of Unstable Angina Pectoris and its Effect on Blood NT-proBNP and HCY Levels
文章编号:
1006-1959（2022）21-0088-04
作者:
王亚飞
（北京市通州区中西医结合医院内科，北京 101100）
Author(s):
WANG Ya-fei
(Department of Internal Medicine,Tongzhou District Hospital of Integrated Traditional Chinese and Western Medicine,Beijing 101100,China)
关键词:
振源胶囊; 不稳定型心绞痛; 氨基末端B型利钠肽前体
Keywords:
Zhenyuan capsule; Unstable angina pectoris; N-terminal B-type natriuretic peptide
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2022.21.020
文献标志码:
A
摘要:
目的 观察振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血氨基末端B型利钠肽前体（NT-proBNP）、同型半胱氨酸（HCY）水平的影响。方法 选取2019年6月-2021年12月我院诊治的82例不稳定型心绞痛患者为研究对象，采用随机数字表法分为对照组和观察组，各41例。对照组采用常规治疗，观察组在对照组基础上给予振源胶囊辅助治疗，比较两组临床疗效、NT-proBNP、HCY、心电图疗效、心绞痛发作次数、心绞痛持续时间、超敏C反应蛋白（hs-CRP）、空腹血糖水平以及临床不良反应发生情况。结果 观察组治疗总有效率为95.12%，高于对照组的80.49%（P＜0.05）；观察组血NT-proBNP、HCY水平低于对照组（P＜0.05）；观察组心电图总有效率为92.68%，高于对照组的78.05%（P＜0.05）；观察组心绞痛发作次数、心绞痛持续时间均小于对照组（P＜0.05）；观察组hs-CRP、空腹血糖水平低于对照组（P＜0.05）；观察组不良反应发生率为7.32%，与对照组的9.76%比较，差异无统计学意义（P＞0.05）。结论 振源胶囊辅助治疗不稳定型心绞痛的疗效良好，可提高治疗总有效率和心电图总有效率，改善心电图ST-T段缺血，减少心绞痛发作次数和持续时间，降低血清NT-proBNP、HCY、hs-CRP以及血糖水平，且不会增加不良反应。
Abstract:
Objective To observe the clinical efficacy of Zhenyuan capsules in adjuvant treatment of unstable angina pectoris and its effect on the levels of N-terminal B-type natriuretic peptide (NT-proBNP) and homocysteine (HCY).Methods A total of 82 patients with unstable angina pectoris diagnosed and treated in our hospital from June 2019 to December 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 41 cases in each group. The control group was treated with conventional therapy, and the observation group was treated with Zhenyuan capsule on the basis of the control group. The clinical efficacy, NT-proBNP, HCY, electrocardiogram efficacy, number of angina pectoris attacks, duration of angina pectoris, high-sensitivity C-reactive protein (hs-CRP), fasting blood glucose level and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.12%, which was higher than 80.49% in the control group (P<0.05). The levels of NT-proBNP and HCY in the observation group were lower than those in the control group(P<0.05). The total effective rate of ECG in the observation group was 92.68%, which was higher than 78.05% in the control group (P<0.05). The frequency and duration of angina pectoris in the observation group were less than those in the control group (P<0.05). The levels of hs-CRP and fasting blood glucose in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 7.32%, which was compared with 9.76% in the control group, the difference was not statistically significant (P>0.05).Conclusion Zhenyuan capsule is effective in the adjuvant treatment of unstable angina pectoris, which can improve the total effective rate of treatment and the total effective rate of electrocardiogram, improve the ST-T segment ischemia of electrocardiogram, reduce the frequency and duration of angina pectoris, and reduce serum NT-proBNP, HCY, hs-CRP and blood glucose levels, without increasing adverse reactions.

参考文献/References:

[1]曹磊.中药对冠心病不稳定型心绞痛患者血管内皮的保护作用[J].世界中医药,2017,12(2):75-78.[2]梁建光,方长庚,李晚泉,等.联合检测超敏C反应蛋白、肌钙蛋白Ⅰ及和肽素对早期不稳定型心绞痛的临床意义研究[J].实用心脑肺血管病杂志,2015(1):16-19.[3]Kwon O,Kang SJ,Kang SH,et al.Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy[J].Circ Cardiovasc Imaging,2017,10(7):e005934.[4]文军,王春梅,丁润会,等.曲美他嗪联合振源胶囊治疗慢性心力衰竭的疗效观察[J].河北医药,2016,37(9):1367-1368.[5]Wang X,Zhao X,Li L,et al.Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease[J].Heart Lung Circ,2016,25(5):459-465.[6]蒋芳萍.振源胶囊辅助治疗不稳定型心绞痛临床疗效及对血NT-proBNP、HCY水平的影响[J].中国煤炭工业医学杂志,2020,23(2):199-203.[7]刘强,王志伟,宋树伟.振源胶囊对不稳定型心绞痛患者高敏ｃ反应蛋白的影响[J].中国病案,2018,19(3):106-109.[8]阚国庆,董淑君,孙洪然,等.养心通络方对不稳定性心绞痛患者血清MMP-9、HCY、PAPP－A水平的影响[J].中成药,2018,40(7):1664-1666.[9]刘泉,张勇,刘海亮,等.替格瑞洛和氯吡格雷治疗不稳定型心绞痛的疗效及成本-效果分析[J]. 中国合理用药探索,2021,18(4):54-56.[10]邵中兴,顾宁.蒲参胶囊联合阿托伐他汀对冠心病合并血脂异常病人血脂水平的影响[J].中西医结合心脑血管病杂志,2016,14(3):282-284.[11]]康玉萍.地尔硫卓与美托洛尔治疗冠心病不稳定型心绞痛患者的疗效与对血脂、运动耐力的影响[J].黑龙江医学,2021,45(23):2525-2526,2529.[12]阮霁诗,彭玲,郑斌,等.美托洛尔联合红花黄色素注射液治疗冠心病不稳定型心绞痛的疗效分析[J].西部医学,2019,31(10):1601-1604.[13]戴小燕,林梅瑟,林芳芬.补气化瘀汤联合艾灸治疗冠心病不稳定型心绞痛的临床疗效及对血清IL-18、hs-CRP的影响[J].浙江中医杂志,2021,56(12):859-860.[14]徐晓鹤.补阳还五汤加减辅助治疗冠心病不稳定型心绞痛的临床疗效[J].内蒙古中医药,2021,40(8):26-27.[15]岳珍珍,何胜男,焦义明.振源胶囊联合心理干预治疗慢性心衰疗效及对患者情绪影响[J].陕西中医,2019,40(3):300-303.[16]王丹,卢迎宏,翟关群,等.振源胶囊联合环磷腺苷治疗冠心病慢性心力衰竭的疗效[J].西北药学杂志,2018,33(6):834-836.[17]李琳,杜鸿瑶,刘立壮,等.振源胶囊治疗冠心病慢性心力衰竭伴焦虑抑郁状态病人临床疗效分析[J].中西医结合心脑血管病杂志,2016,14(12):1319-1321.[18]王晓勇,梁森.振源胶囊联合舍曲林治疗心神失养型郁证43例[J].江西中医药,2017,48(1):39-41.[19]呼军珍,王爽.环磷腺苷葡胺联合振源胶囊治疗慢性心力衰 竭的临床效果分析[J].西北国防医学杂志,2017,38(12):812-815.[20]刘佳,冯辉,杨晓艳,等.祛风稳斑汤对不稳定型心绞痛(痰瘀互结证)hs-CRP、Hcy、NT-proBNP的影响[J].中国中医急症,2016,25(11):2142-2144.

相似文献/References:

[1]张 毅.替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响[J].医学信息,2022,35(13):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
　ZHANG Yi.Effect of Ticagrelor on Ischemic Events and Inflammatory Factors in Patients with Unstable Angina Pectoris After PCI[J].Journal of Medical Information,2022,35(21):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
[2]周忠梅.前列地尔辅助常规治疗冠心病不稳定型心绞痛的效果及对患者凝血功能的影响[J].医学信息,2019,32(20):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
　ZHOU Zhong-mei.Effect of Alprostadil on Routine Treatment of Unstable Angina Pectoris in Coronary Heart Disease and its Effect on Coagulation Function in Patients[J].Journal of Medical Information,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
[3]杨 晴,郭秋红.血栓前状态分子标志物变化在不稳定型心绞痛合并高血压诊断中的价值[J].医学信息,2020,33(02):172.[doi:10.3969/j.issn.1006-1959.2020.02.055]
　YANG Qing,GUO Qiu-hong.Value of Molecular Marker Changes in Prethrombotic State in the Diagnosis of Unstable Angina Pectoris Complicated with Hypertension[J].Journal of Medical Information,2020,33(21):172.[doi:10.3969/j.issn.1006-1959.2020.02.055]
[4]潘小玉,张再伟,李 虎.吲哚布芬治疗不稳定型心绞痛的有效性和安全性的Meta分析[J].医学信息,2020,33(14):80.[doi:10.3969/j.issn.1006-1959.2020.14.023]
　PAN Xiao-yu,ZHANG Zai-wei,LI Hu.Meta Analysis of the Efficacy and Safety of Indobufen in the Treatment of Unstable Angina[J].Journal of Medical Information,2020,33(21):80.[doi:10.3969/j.issn.1006-1959.2020.14.023]
[5]杨岸霖.不稳定型心绞痛的发病机制及药物研究[J].医学信息,2022,35(01):70.[doi:10.3969/j.issn.1006-1959.2022.01.017]
　YANG An-lin.The Pathogenesis and Drug Research of Unstable Angina Pectoris[J].Journal of Medical Information,2022,35(21):70.[doi:10.3969/j.issn.1006-1959.2022.01.017]
[6]刘 杰,贾 志.NLR、RBP-4及MPV与不稳定型心绞痛患者冠状动脉病变程度的相关性分析[J].医学信息,2022,35(03):91.[doi:10.3969/j.issn.1006-1959.2022.03.021]
　LIU Jie,JIA Zhi.Correlation Analysis of NLR, RBP-4 and MPV with Coronary Artery Lesionsin Patients with Unstable Angina Pectoris[J].Journal of Medical Information,2022,35(21):91.[doi:10.3969/j.issn.1006-1959.2022.03.021]
[7]耿倩倩.预见性护理在不稳定型心绞痛患者中的应用效果[J].医学信息,2023,36(22):175.[doi:10.3969/j.issn.1006-1959.2023.22.041]
　GENG Qian-qian.Application Effect of Predictive Nursing in Patients with Unstable Angina Pectoris[J].Journal of Medical Information,2023,36(21):175.[doi:10.3969/j.issn.1006-1959.2023.22.041]

更新日期/Last Update: 1900-01-01